Literature DB >> 10861480

Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women.

R Tedeschi1, L Caggiari, I Silins, I Kallings, A Andersson-Ellström, P De Paoli, J Dillner.   

Abstract

The mode of transmission of human herpesvirus 8 (HHV8) was investigated in two seroepidemiological studies of Swedish women who completed a questionnaire about sexual behavior. Seropositivity for HHV8 antibodies, measured using an indirect immunofluorescence assay, was linked to a high number (>10) of sexual partners (P < 0.004). It also correlated strongly with a history of other sexually transmitted diseases (STD; P < 0.0001), in particular with a history of Chlamydia trachomatis infection and condyloma acuminata. There was appreciable HHV8 seropositivity already among virginal or monogamous women (9%). In summary, HHV8 transmission to women in Sweden may occur nonsexually. When sexual transmission occurs, it appears to be associated with high risk-taking sexual behavior. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861480

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.

Authors:  R Tedeschi; M Enbom; E Bidoli; A Linde; P De Paoli; J Dillner
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Sexual activity and Kaposi's sarcoma among human immunodeficiency virus type 1 and human herpesvirus type 8-coinfected men.

Authors:  Eric W Nawar; Stephen R Cole; Homayoon Farzadegan; Mallory D Witt; Frank J Jenkins; Joseph B Margolick; John P Phair; Lisa P Jacobson
Journal:  Ann Epidemiol       Date:  2008-05-27       Impact factor: 3.797

Review 3.  Laboratory diagnosis of human herpesvirus 8 infection in humans.

Authors:  R Tedeschi; J Dillner; P De Paoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-12-11       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.